Neurosense Therapeutics is trading at $0.72 (10.5% up) following its announcement to file a New Drug Submission with Health Canada for its ALS therapy, PrimeC.
- The regulatory filing follows a constructive pre-filing meeting and highlights long-term survival benefits observed in clinical data.
- Shares are extending a bounce from the July 23 close of $0.66 as investors re-rate the stock on regulatory momentum and pipeline potential.